Merck, Moderna Say Melanoma Skin Cancer Treatment Meets Main Goal In Late-Stage Trial
MRK•Additional Reuters note
Further company coverage: MRK.N
Late-stage melanoma trial meets primary endpoint
Aug. 19 (Reuters) - Merck & Co Inc MRK.N:
- Merck and Moderna announce positive results from Phase 3 INTerpath-001 trial for patients with completely resected stage IIB-IV melanoma
- Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival
- Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met a key secondary endpoint of distant metastasis-free survival
- Safety profiles of intismeran and Keytruda in the trial were consistent with prior reported studies for the combination
- Merck and Moderna will engage with regulators on filing submissions for intismeran autogene in combination with Keytruda
